Repligen Corporation (RGEN) News
Filter RGEN News Items
RGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RGEN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RGEN News From Around the Web
Below are the latest news stories about REPLIGEN CORP that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
3 US Stocks Including Advanced Energy Industries That May Be Priced Below Estimated ValueAs the U.S. stock market navigates a period of fluctuating indices and economic data that has investors closely watching interest rate trends, opportunities may arise for discerning investors to identify stocks priced below their estimated value. In this environment, understanding fundamental metrics and market conditions can be key in recognizing undervalued stocks such as Advanced Energy Industries and others that might offer potential value propositions. |
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible |
Repligen Launches the CTech™ SoloVPE® PLUS SystemNext-Generation At-Line Concentration Measurement for Bioprocessing SoloVPE PLUS System Repligen's next-generation SoloVPE PLUS System for faster, more precise and reproducible protein concentration measurements. WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technolo |
Repligen Corporation (RGEN) Fell Along with PeersBrown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The Small Company Fund returned 8.48% in the quarter, roughly in line with the Russell 2000 Growth index’s 8.41% return. The Fund has only gained 1.80% year […] |
BioLife Solutions Appoints Tony J. Hunt to its Board of DirectorsBioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. |
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability ReportWALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply C |
Several Factors Lifted Repligen Corporation (RGEN) in Q3TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96% (gross) and […] |
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed ColumnsBreakthrough Innovation for the Purification of mRNA Therapeutics and VaccinesWALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of AVIPure® dsRNA Clear OPUS® columns, a groundbreaking solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity chromatography offering marries Repligen’s breakthrough dsRNA purific |
3 US Stocks Estimated To Be Trading At Discounts Up To 49.1%As the U.S. stock market reaches new heights, with the Dow Jones Industrial Average closing at a record high and major indices posting weekly gains, investors are increasingly on the lookout for opportunities that may be trading below their intrinsic value. In this environment of rising markets and economic optimism, identifying undervalued stocks can offer potential entry points for those seeking to capitalize on discrepancies between current prices and perceived true worth. |